Kraj: Singapur
Język: angielski
Źródło: HSA (Health Sciences Authority)
Sodium Polystyrene Sulfonate
GOLDPLUS UNIVERSAL PTE LTD
V03AE01
POWDER, FOR SUSPENSION
Sodium Polystyrene Sulfonate 1g/g
ORAL, RECTAL
Prescription Only
Sava Healthcare Ltd
ACTIVE
2023-06-14
INFORMATION FOR THE CONSUMER JAMP Sodium Polystyrene Sulfonate Powder for Suspension, 1 g / g DESCRIPTION OF THE PRODUCT JAMP Sodium Polystyrene Sulfonate (sodium polystyrene sulfonate) is a golden brown, odorless fine powder with a characteristic taste of sodium polystyrene sulfonate. JAMP Sodium Polystyrene Sulfonate is a cation-exchange resin prepared in the sodium phase, with an in vivo exchange capacity of approximately 1 mmol (in vitro approximately 3.1 mmol) of potassium per gram. The sodium content is approximately 4.1 mmol (94.3 mg) per gram of the drug. JAMP Sodium Polystyrene Sulfonate can be administered either orally or as an enema. What the medicinal ingredient is: Sodium polystyrene sulfonate What the non-medicinal ingredients are: None What dosage forms it comes in: Powder for suspension What it does: Sodium polystyrene sulfonate is not absorbed from the gastrointestinal tract. As the resin passes through the gastrointestinal tract, the resin removes the potassium ions by exchanging it for sodium ions. Most of this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. Potassium exchange also occurs in the colon following retention of the resin, when administered as an enema. The efficiency of this process is limited and unpredictable. It commonly approximates the order of 33 per cent but the range is so large that definite indices of electrolyte balance must be clearly monitored. Metabolic data are unavailable. INDICATION JAMP Sodium Polystyrene Sulfonate is indicated for the treatment of hyperkalemia. CONTRAINDICATIONS JAMP Sodium Polystyrene Sulfonate should not be administered to patients with the following conditions: • serum potassium <5 mmol / L • history of hypersensitivity to polystyrene sulfonate resins • obstructive bowel disease JAMP Sodium Polystyrene Sulfonate should not be administered _orally_ to neonates or in neonates with reduced gut motility (postoperatively or drug induced). POSSIBLE SIDE EFFECTS Side effect Przeczytaj cały dokument
JAMP Sodium Polystyrene Sulfonate Powder for Suspension, 1 g / g DESCRIPTION OF THE PRODUCT JAMP Sodium Polystyrene Sulfonate (sodium polystyrene sulfonate) is a golden brown, odorless fine powder with a characteristic taste of sodium polystyrene sulfonate. JAMP Sodium Polystyrene Sulfonate is a cation-exchange resin prepared in the sodium phase, with an in vivo exchange capacity of approximately 1 mmol (in vitro approximately 3.1 mmol) of potassium per gram. The sodium content is approximately 4.1 mmol (94.3 mg) per gram of the drug. JAMP Sodium Polystyrene Sulfonate can be administered either orally or as an enema. What dosage forms it comes in: Powder for suspension ACTION The action of this product is to partially release sodium ions from the resin and replace them by potassium ions as the resin passes along the intestine or is retained in the colon after administration by enema. For the most part, this action occurs in the large intestine which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33% but the range is so large that definitive indices of electrolyte balance must be clearly monitored. Frequent serum potassium determinations, at least once every 24 hours, should be done in order to adjust the individual dosage. The action of this product can be accomplished by either oral administration or by retention enema. INDICATION JAMP Sodium Polystyrene Sulfonate is indicated for the treatment of hyperkalemia. WARNINGS Since the effective lowering of serum potassium with this product may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia associated with states of rapid tissue breakdown (e.g., burns and renal failure) or hyperkalemia so marked as to constitute a medical emergency. Therefore, other definitive measures, including dialysis, should always be considered and may be imperative. Serious potassium deficiency can Przeczytaj cały dokument